Drug-Induced Immune-Mediated Thrombocytopenia Secondary To Durvalumab Use

Sean C. Dougherty,Alia C. Lynch,Richard D. Hall

CLINICAL CASE REPORTS（2021）

引用 3|浏览3

暂无评分

摘要

Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune-related adverse events; here, we described thrombocytopenia secondary todurvalumab.

查看译文

关键词

ITP, medical oncology, pharmacokinetics, platelets-acquired platelet disorders, thrombocytopenia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要